TOP

*Name

Phone

*Email

*Company/Institute

Consultation content

*Verification code

Contact Sales


Sales Image

Contact Sales Assistant


Sales Assistant Image

Contact PM


PM Image
AI Antibodies from Sequence to Protein: Fully Automated, Significantly Reducing R&D Budgets!
Release time:2026-07-15
Share:
Antibody discovery is undergoing a profound transformation. Traditionally, scientists have "screened" antibodies using technologies like hybridomas or phage display—searching for a needle in a haystack of massive antibody libraries, which is inefficient and time-consuming. Today, generative AI can "design antibody sequences from scratch" based on target characteristics, with platforms capable of virtually screening 100 million candidate molecules within 48 hours, upgrading antibody discovery from "random collisions" to "precise mapping."

 

But a question arises: AI can design it, but who can quickly verify it?

 

AI can generate thousands of antibody sequences on a computer, but for each sequence to become a true antibody protein, it must go through a series of wet experimental steps including gene synthesis, vector construction, cell transfection, and antibody expression. Traditional gene synthesis and antibody expression services still remain at the model of "manual ordering, individual synthesis."

 

GentleGen is leveraging full-process automation to accelerate a new model for AI + early antibody R&D—IgG monoclonal antibodies at 49.9 USD/clones, VHH nanobodies at 29.9 USD/clones, and each tube comes with an additional 800 μl supernatant, making AI-powered "high-throughput screening" a true routine in every laboratory.

 

What do these numbers mean? This means that the budget previously only needed to synthesize one or two antibodies can now be completed by GentleGen for high-throughput screening of dozens of antibodies. More importantly, each antibody comes with 800 μl of antibody supernatant that can be directly used for functional validation—eliminating purification steps, skipping intermediate steps, and ready to use right on the go. From genes to antibodies, a one-stop direct downstream experiment.

 

Relying on its independently developed GentSyn-Exp3.0G-Lab fully automated production line, GentleGen has built a one-stop, high-throughput technology platform covering gene design, synthesis, validation, protein expression, and antibody development. More importantly, GentleGen's high-throughput antibody supernatant expression service delivers unpurified antibody supernatants directly, eliminating cumbersome purification steps and allowing you to use them directly downstream for functional validation, affinity evaluation, and preliminary screening experiments.

 

企业微信截图_1784091960872

 

  • High-throughput production: production throughput exceeds 3,000 samples.

  • High cost-effectiveness: High-throughput expression screening effectively reduces the detection cost of individual samples.

  • One-stop solution: integrating resources to provide full-process services from gene synthesis to antibody expression.

 

Starting at 49.9 USD, plus 800 μl of Shangqing Clear—this isn't a promotional gimmick, but a universal benefit brought by the automation revolution.

 

GentleGen's G-Lab fully automated gene antibody platform will continuously inject strong momentum into your biopharmaceutical innovation projects through cutting-edge automation technology, rapid delivery capabilities, and rigorous safety and quality control! GentleGen can provide related services. For detailed information about related services, you can send an email to marketing@gentlegen.com.

Pre-sales consulting

Pre-sales consulting

A more reliable solution for your needs.
Download

Download

Welcome to our product library.
Sales network

Sales network

Complete sales and service network to ensure product quality.
Event Promotions

Event Promotions

Add to cart now and enjoy this shopping extravaganza!